Chiara Lambertini

1.2k total citations · 1 hit paper
26 papers, 862 citations indexed

About

Chiara Lambertini is a scholar working on Oncology, Cancer Research and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Chiara Lambertini has authored 26 papers receiving a total of 862 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 9 papers in Cancer Research and 8 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Chiara Lambertini's work include HER2/EGFR in Cancer Research (14 papers), Breast Cancer Treatment Studies (9 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). Chiara Lambertini is often cited by papers focused on HER2/EGFR in Cancer Research (14 papers), Breast Cancer Treatment Studies (9 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). Chiara Lambertini collaborates with scholars based in Switzerland, United States and Germany. Chiara Lambertini's co-authors include G. Paolo Dotto, Reinhard Dummer, Sanne Lysbet de Haas, Sherene Loi, Monika Patre, Roberto Salgado, Michelino De Laurentiis, Francisco J. Esteva, Jigna Shah and Mark Beresford and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Chiara Lambertini

22 papers receiving 858 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial

2020 280 citations Leisha A. Emens, Francisco J. Esteva et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Chiara Lambertini Switzerland	15	607	250	202	174	148	26	862
Natsuko Imaizumi Switzerland	11	398 0.7×	373 1.5×	96 0.5×	115 0.7×	153 1.0×	11	765
María Vieito Spain	16	510 0.8×	273 1.1×	90 0.4×	256 1.5×	337 2.3×	100	907
Gerrit K. Hooijer Netherlands	15	565 0.9×	261 1.0×	122 0.6×	169 1.0×	298 2.0×	34	889
Frédérique Berger France	19	517 0.9×	420 1.7×	105 0.5×	323 1.9×	411 2.8×	64	1.0k
Dan Lu China	9	203 0.3×	458 1.8×	94 0.5×	85 0.5×	131 0.9×	16	694
M. Gabriela Kuba United States	10	529 0.9×	399 1.6×	101 0.5×	110 0.6×	211 1.4×	17	780
W. H. Miller United States	9	486 0.8×	283 1.1×	104 0.5×	166 1.0×	88 0.6×	17	723
Gnana P. Krishnamoorthy United States	12	449 0.7×	457 1.8×	61 0.3×	178 1.0×	137 0.9×	16	1.3k
Hao Xing China	16	272 0.4×	191 0.8×	69 0.3×	200 1.1×	249 1.7×	30	982
Daniel C. Koboldt United States	9	461 0.8×	313 1.3×	189 0.9×	202 1.2×	247 1.7×	19	804

Countries citing papers authored by Chiara Lambertini

Since Specialization

Citations

This map shows the geographic impact of Chiara Lambertini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chiara Lambertini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chiara Lambertini more than expected).

Fields of papers citing papers by Chiara Lambertini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chiara Lambertini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chiara Lambertini. The network helps show where Chiara Lambertini may publish in the future.

Co-authorship network of co-authors of Chiara Lambertini

This figure shows the co-authorship network connecting the top 25 collaborators of Chiara Lambertini. A scholar is included among the top collaborators of Chiara Lambertini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chiara Lambertini. Chiara Lambertini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lambertini, Matteo, Deirdre Allegranza, Ruediger P. Laubender, et al.. (2025). Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients. JNCI Journal of the National Cancer Institute. 117(11). 2317–2326.

Schmid, Peter, Thomas Bachelot, Giampaolo Bianchini, et al.. (2024). Abstract PO3-20-01: ASTEFANIA: a Phase III study of ado-trastuzumab emtansine plus atezolizumab or placebo as adjuvant therapy in patients with residual invasive breast cancer after neoadjuvant HER2-targeted therapy and chemotherapy. Cancer Research. 84(9_Supplement). PO3–20. 1 indexed citations

Haas, Sanne Lysbet de, Dennis J. Slamon, Miguel Martín, et al.. (2023). Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE). Breast Cancer Research. 25(1). 2–2. 28 indexed citations

Gupta, Shilpa, Omar Alhalabi, Aristotelis Bamias, et al.. (2023). 2409TiP A global, multicentre, open-label, randomised phase II trial of tobemstomig (tobe) with or without tiragolumab (tira) vs atezolizumab (atezo) in patients (pts) with untreated metastatic urothelial cancer (mUC) ineligible for platinum-based chemotherapy (chemo). Annals of Oncology. 34. S1225–S1225.

Denkert, Carsten, Chiara Lambertini, Peter A. Fasching, et al.. (2023). Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer. Clinical Cancer Research. 29(8). 1569–1581. 23 indexed citations

Huober, Jens, Carlos H. Barrios, Naoki Niikura, et al.. (2022). Atezolizumab With Neoadjuvant Anti–Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial. Journal of Clinical Oncology. 40(25). 2946–2956. 82 indexed citations

Loibl, Sibylle, Chiun‐Sheng Huang, Max S. Mano, et al.. (2022). Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE. npj Breast Cancer. 8(1). 106–106. 22 indexed citations

Hurvitz, Sara A., Thomas Bachelot, Giampaolo Bianchini, et al.. (2022). ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer. Future Oncology. 18(32). 3563–3572. 15 indexed citations

Pietrantonio, Filippo, Paolo Manca, Sara E. Bellomo, et al.. (2022). HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial. Clinical Cancer Research. 29(3). 571–580. 15 indexed citations

10.

Metzger, Otto, Chiara Lambertini, IE Krop, et al.. (2021). 42O Biomarker analysis from KAITLIN, a randomised phase III study of adjuvant trastuzumab emtansine (TDM-1; K) plus pertuzumab (P) versus trastuzumab (H) plus taxane (T) plus P after anthracyclines (AC) for high-risk HER2-positive early breast cancer (EBC). Annals of Oncology. 32. S37–S38. 3 indexed citations

11.

Carron, Michele, et al.. (2021). Corrected versus total body weight for dosage of sugammadex in morbidly obese patients. A randomized, double-blind, controlled trial. Minerva Anestesiologica. 87(3). 371–373. 1 indexed citations

12.

Huober, Jens, Carlos H. Barrios, Naoki Niikura, et al.. (2021). VP6-2021: IMpassion050: A phase III study of neoadjuvant atezolizumab + pertuzumab + trastuzumab + chemotherapy (neoadj A + PH + CT) in high-risk, HER2-positive early breast cancer (EBC). Annals of Oncology. 32(8). 1061–1062. 23 indexed citations

13.

Emens, Leisha A., Francisco J. Esteva, Mark Beresford, et al.. (2020). Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. The Lancet Oncology. 21(10). 1283–1295. 280 indexed citations breakdown →

14.

Denkert, Carsten, Chiara Lambertini, Peter A. Fasching, et al.. (2020). Biomarker data from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer.. Journal of Clinical Oncology. 38(15_suppl). 502–502. 21 indexed citations

15.

Lambertini, Chiara, Patrizia Barzaghi-Rinaudo, Lisa D’Amato, et al.. (2013). Evaluation of somatostatin receptor subtype expression in human neuroendocrine tumors using two sets of new monoclonal antibodies. Regulatory Peptides. 187. 35–41. 20 indexed citations

16.

Prezioso, Lucia, Sabrina Bonomini, Chiara Lambertini, et al.. (2013). Haploidentical Stem Cell Transplantation After Negative Depletion Of T Cells Expressing The αβ Chain Of The T-Cell Receptor (TCR) For Adults With Hematological Malignancies. Blood. 122(21). 4609–4609. 3 indexed citations

17.

Schmid, Herbert, Chiara Lambertini, Patrizia Barzaghi-Rinaudo, et al.. (2011). Monoclonal Antibodies against the Human Somatostatin Receptor Subtypes 1–5: Development and Immunohistochemical Application in Neuroendocrine Tumors. Neuroendocrinology. 95(3). 232–247. 27 indexed citations

18.

Lambertini, Chiara, Serafino Pantano, & G. Paolo Dotto. (2010). Differential Control of Notch1 Gene Transcription by Klf4 and Sp3 Transcription Factors in Normal versus Cancer-Derived Keratinocytes. PLoS ONE. 5(4). e10369–e10369. 36 indexed citations

19.

Kolev, Vihren N., Anna Mandinova, Juan Guinea‐Viniegra, et al.. (2008). EGFR signalling as a negative regulator of Notch1 gene transcription and function in proliferating keratinocytes and cancer. Nature Cell Biology. 10(8). 902–911. 159 indexed citations

20.

Valentini, Alessandra, Chiara Lambertini, Monica Taborelli, et al.. (2005). In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas. Annals of Oncology. 16(7). 1169–1176. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact